Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:CING NYSE:CLDI NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.25-0.4%$2.35$0.95▼$2.85$20.29M0.2277,160 shs50,498 shsCINGCingulate$3.90+2.9%$4.50$3.02▼$7.00$20.51M-0.76152,173 shs147,066 shsCLDICalidi Biotherapeutics$1.60+1.9%$5.04$1.51▼$46.68$5.48M1.08637,444 shs244,892 shsNEUPNeuphoria Therapeutics$11.89-0.3%$8.31$2.12▼$13.34$22.41M0.5765,082 shs40,781 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-3.42%-2.16%-8.87%+13.00%-5.44%CINGCingulate+2.43%-3.81%-30.07%-13.07%-43.52%CLDICalidi Biotherapeutics-0.63%-8.19%-78.34%-63.25%-88.62%NEUPNeuphoria Therapeutics-8.31%-2.38%+57.05%+73.51%+1,191,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.25-0.4%$2.35$0.95▼$2.85$20.29M0.2277,160 shs50,498 shsCINGCingulate$3.90+2.9%$4.50$3.02▼$7.00$20.51M-0.76152,173 shs147,066 shsCLDICalidi Biotherapeutics$1.60+1.9%$5.04$1.51▼$46.68$5.48M1.08637,444 shs244,892 shsNEUPNeuphoria Therapeutics$11.89-0.3%$8.31$2.12▼$13.34$22.41M0.5765,082 shs40,781 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-3.42%-2.16%-8.87%+13.00%-5.44%CINGCingulate+2.43%-3.81%-30.07%-13.07%-43.52%CLDICalidi Biotherapeutics-0.63%-8.19%-78.34%-63.25%-88.62%NEUPNeuphoria Therapeutics-8.31%-2.38%+57.05%+73.51%+1,191,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 3.00Buy$10.00344.44% UpsideCINGCingulate 3.00Buy$26.25573.08% UpsideCLDICalidi Biotherapeutics 0.00N/AN/AN/ANEUPNeuphoria Therapeutics 3.00Buy$21.0076.62% UpsideCurrent Analyst Ratings BreakdownLatest CLDI, CING, NEUP, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025NEUPNeuphoria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.008/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.25N/AN/A$4.64 per share0.48CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/A($2.32) per shareN/ANEUPNeuphoria Therapeutics$10K2,235.32N/AN/A$15.85 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)CINGCingulate-$15.55M-$4.100.00N/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)CLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)Latest CLDI, CING, NEUP, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/29/2025N/ANEUPNeuphoria Therapeutics-$1.26N/AN/AN/AN/AN/A9/25/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/A8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87CINGCingulateN/A1.521.52CLDICalidi BiotherapeuticsN/A0.190.19NEUPNeuphoria TherapeuticsN/A11.0111.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%CINGCingulate41.31%CLDICalidi Biotherapeutics12.53%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%CINGCingulate4.04%CLDICalidi Biotherapeutics6.70%NEUPNeuphoria Therapeutics0.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableCINGCingulate205.41 million5.19 millionNot OptionableCLDICalidi Biotherapeutics383.43 million20.04 millionN/ANEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ACLDI, CING, NEUP, and AYTU HeadlinesRecent News About These CompaniesNeuphoria Therapeutics initiated with a Buy at Lucid CapitalSeptember 4 at 8:17 PM | msn.comNeuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trialSeptember 4 at 8:17 PM | msn.comNeuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)September 4 at 7:00 AM | globenewswire.comEquities Analysts Offer Predictions for NEUP Q4 EarningsAugust 30, 2025 | americanbankingnews.comNeuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comNeuphoria Therapeutics' (NEUP) Buy Rating Reaffirmed at HC WainwrightAugust 28, 2025 | americanbankingnews.comDementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsightJuly 17, 2025 | finance.yahoo.comNEUP Neuphoria Therapeutics Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comNeuphoria Therapeutics Inc. (NEUP) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 27, 2025 | globenewswire.comNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21, 2025 | finanznachrichten.deNeuphoria Provides First Quarter 2025 Business UpdatesMay 20, 2025 | globenewswire.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comNeuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comHere's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep goingFebruary 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Costco and Ross: 2 Ways to Play the Consumer DivideBy Chris Markoch | August 24, 2025Oklo’s Stock Is Set up for a Correction—Buy It When It BouncesBy Thomas Hughes | August 12, 2025CLDI, CING, NEUP, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.25 -0.01 (-0.44%) Closing price 04:00 PM EasternExtended Trading$2.27 +0.02 (+0.93%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Cingulate NASDAQ:CING$3.90 +0.11 (+2.90%) Closing price 04:00 PM EasternExtended Trading$3.97 +0.07 (+1.79%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Calidi Biotherapeutics NYSE:CLDI$1.60 +0.03 (+1.91%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Neuphoria Therapeutics NASDAQ:NEUP$11.89 -0.03 (-0.25%) As of 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon Share Price Has Plenty of Room Left to Fall Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Lockheed Martin: Is the Market Overlooking This Defensive Giant? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
